



# JFL LIFE SCIENCES LIMITED

**Date:** January 29, 2026

To,  
**The Manager,**  
**Listing Department**  
**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

**NSE Symbol: JFLLIFE; ISIN: INEOLA901015**

**Subject: Outcome of Board Meeting held on Thursday, January 29, 2026**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of JFL Life Sciences Limited ("the Company") has been held on Thursday, January 29, 2026 at 02:00 P.M. which **concluded at 03:25 PM** and Board has inter alia considered and approved the Standalone Un-audited financial results for the quarter & nine months ended December 31, 2025.

A copy of the said unaudited financial results along with the Limited Review Report are enclosed herewith in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking You

Yours Truly,  
**For JFL LIFE SCIENCES LIMITED**

**SMIRAL ASHWINKUMAR PATEL**  
Managing director  
DIN: 00769486

**Encl:** A/a

## JFL Life Sciences Limited

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELLITE, AHMEDABAD 380015  
 Tel No. +91-93772 95575, Email Id :- info@jflifesciences.com, www.jflifesciences.com

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED ON 31ST DECEMBER, 2025

(Rs. In Lakhs)

Sr. No.	PARTICULARS.	Quarter Ended on			Nine Months Ended on		Year Ended on (Audited)
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	
<b>INCOMES</b>							
I	Revenue from Operations	2,683.62	2,990.65	2,124.83	6,832.81	7,030.42	8,204.23
II	Other Income	140	120	104	288	148	101
III	Total Income (I + II)	2,685.02	2,991.85	2,125.87	6,833.69	7,031.90	8,205.24
<b>EXPENSES</b>							
(a)	Cost of materials consumed	2,299.41	2,664.99	1,910.15	5,723.63	6,192.05	6,677.44
(b)	Changes of Inventories of Finished Goods, Work in Progress, Stock in Trade	(184)	(1331)	(2321)	(706)	(9071)	(6630)
(c)	Employee benefits expense	26.80	26.45	30.69	76.46	126.99	101.09
(d)	Finance Cost	38.42	44.26	20.14	107.16	73.66	108.12
(e)	Depreciation and Amortisation Expenses	26.86	26.83	15.93	80.09	63.74	99.25
(f)	Other Expenses	24.58	21.02	72.99	220.24	121.62	672.10
	<b>TOTAL EXPENSES (IV (a to f)</b>	<b>2,414.22</b>	<b>2,770.24</b>	<b>2,026.70</b>	<b>6,200.52</b>	<b>6,497.36</b>	<b>7,591.70</b>
V	<b>Profit / (Loss) before Exceptional Items and Tax. (III-IV)</b>	<b>270.80</b>	<b>221.61</b>	<b>99.17</b>	<b>635.17</b>	<b>544.54</b>	<b>613.54</b>
VI	Exceptional Items & Extraordinary Item	-	-	-	-	-	-
VII	<b>Profit / (Loss) Before Tax. (V-VI)</b>	<b>270.79</b>	<b>221.61</b>	<b>99.17</b>	<b>635.17</b>	<b>544.54</b>	<b>613.54</b>
<b>TAX EXPENSES</b>							
(a)	Current Tax	69.52	70.84	24.26	162.95	133.41	152.78
(b)	Deferred Tax	(0.59)	(46.66)	0.69	(171)	3.65	44.90
	<b>Total Tax Expenses</b>	<b>68.93</b>	<b>24.18</b>	<b>24.95</b>	<b>161.24</b>	<b>137.06</b>	<b>197.69</b>
IX	<b>NET PROFIT / (LOSS) FOR THE PERIOD</b>	<b>201.86</b>	<b>197.43</b>	<b>74.22</b>	<b>473.93</b>	<b>407.48</b>	<b>415.86</b>
X	Items that will not be reclassified to profit or loss						
(i)	Re-measurement gains on defined benefit plans	(0.50)	(0.76)	-	(1.18)	-	0.36
	<b>Other comprehensive income for the year, net of tax</b>	<b>(0.50)</b>	<b>(0.76)</b>	<b>-</b>	<b>(1.18)</b>	<b>-</b>	<b>0.36</b>
	<b>Total comprehensive income for the year</b>	<b>202.36</b>	<b>198.19</b>	<b>74.22</b>	<b>475.11</b>	<b>407.48</b>	<b>415.50</b>
XI	<b>Paid up Equity Share Capital (Amount in lacs)</b>	<b>3,299.53</b>	<b>3,299.53</b>	<b>3,299.53</b>	<b>3,299.53</b>	<b>3,299.53</b>	<b>3,299.53</b>
	Rs. 10 Face value per share	Rs. 10/-					
XII	<b>Earnings Per Share (In Rupees) from</b>						
(i)	Basic	0.61	0.60	0.22	1.44	1.23	1.26
(ii)	Diluted	0.61	0.60	0.22	1.44	1.23	1.26

#### NOTES:

- These financial results were reviewed by the Board of Directors and Audit Committee thereafter have been approved by the board of directors at its meeting held on January 29th, 2026. The Statutory Auditors have carried out Review of the Unaudited Financial Results for the Quarter and Period ended on 31st Dec, 2025
- Financial results for the periods presented have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

3 Company has only one reportable segment - Pharmaceuticals Manufacturing

4 Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.

For JFL Life Sciences Limited

Smiral A. Patel  
 Managing Director  
 DIN : 00769486  
 Date: January 29, 2026  
 Place : Ahmedabad



Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr.Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.

Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.

Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jflifesciences.com | Website : www.jflifesciences.com

## LIMITED REVIEW REPORT

### Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of JFL LIFE SCIENCES LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

The Board of Directors

JFL LIFE SCIENCES LIMITED


309, Satyam Mall, Opp. Saman Complex,  
Nr. Vishweshwar Mahadev Mandir, Settelite,  
Ahmedabad, Gujarat, India, 380015

1. We have reviewed the accompanying statement of unaudited financial results of **JFL Life Sciences Limited** (the 'Company') for the quarter ended December 31, 2025 and the year-to-date results for the period 01 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the presentation and disclosure requirement of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34, Prescribed under section 133 of the Act , and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doshi Doshi & Co,  
Chartered Accountants  
Firm Registration No.: 153683W

  
Chintan R. Doshi  
Partner  
Membership No.: 158931  
UDIN: 26158931CEYUJU9034



Place: Ahmedabad  
Date: January 29, 2025